![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 3
2016
Vastesaeger, Nathan; Kutzbach, Abraham Garcia; Amital, Howard; Pavelka, Karel; Alicia Lazaro, Maria; Moots, Robert J.; Wollenhaupt, Jürgen; Zerbini, Cristiano A. F.; Louw, Ingrid; Combe, Bernard; Beaulieu, Andre; Schulze-Koops, Hendrik; Dasgupta, Bhaskar; Fu, Bo; Huyck, Susan; Weng, Haoling H.; Govoni, Marinella und Durez, Patrick
(2016):
Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab.
In: Rheumatology, Bd. 55, Nr. 8: S. 1466-1476
2014
Combe, Bernard; Dasgupta, Bhaskar; Louw, Ingrid; Pal, Sarvajeet; Wollenhaupt, Jürgen; Zerbini, Cristiano A. F.; Beaulieu, Andre D.; Schulze-Koops, Hendrik; Durez, Patrick; Yao, Ruji; Vastesaeger, Nathan und Weng, Haoling H.
(2014):
Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study.
In: Annals of the rheumatic diseases, Bd. 73, Nr. 8: S. 1477-1486
[PDF, 1MB]
McInnes, Iain B.; Sieper, Joachim; Braun, Juergen; Emery, Paul; Heijde, Desiree van der; Isaacs, John D.; Dahmen, Georg; Wollenhaupt, Jürgen; Schulze-Koops, Hendrik; Kogan, Joseph; Ma, Shenglin; Schumacher, Martin M.; Bertolino, Arthur P.; Hueber, Wolfgang und Tak, Paul P.
(2014):
Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial.
In: Annals of the rheumatic diseases, Bd. 73, Nr. 2: S. 349-356
[PDF, 950kB]